Sabine Krebs

657 total citations
22 papers, 472 citations indexed

About

Sabine Krebs is a scholar working on Pediatrics, Perinatology and Child Health, Geriatrics and Gerontology and Surgery. According to data from OpenAlex, Sabine Krebs has authored 22 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pediatrics, Perinatology and Child Health, 6 papers in Geriatrics and Gerontology and 4 papers in Surgery. Recurrent topics in Sabine Krebs's work include Pharmaceutical studies and practices (11 papers), Pharmaceutical Practices and Patient Outcomes (6 papers) and Pharmacovigilance and Adverse Drug Reactions (4 papers). Sabine Krebs is often cited by papers focused on Pharmaceutical studies and practices (11 papers), Pharmaceutical Practices and Patient Outcomes (6 papers) and Pharmacovigilance and Adverse Drug Reactions (4 papers). Sabine Krebs collaborates with scholars based in Germany, Israel and Austria. Sabine Krebs's co-authors include Kay Brune, Uta Muth‐Selbach, Harald Dormann, Eckhart G. Hahn, Manfred Criegee‐Rieck, Irmgard Tegeder, H. T. Schneider, Gerd Geißlinger, Micha Levy and Antje Neubert and has published in prestigious journals such as PEDIATRICS, Clinical Pharmacology & Therapeutics and Alimentary Pharmacology & Therapeutics.

In The Last Decade

Sabine Krebs

19 papers receiving 442 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sabine Krebs Germany 10 208 206 188 82 55 22 472
C. Noblet France 8 280 1.3× 149 0.7× 156 0.8× 148 1.8× 44 0.8× 17 633
William N. Kelly United States 13 168 0.8× 140 0.7× 274 1.5× 60 0.7× 156 2.8× 47 671
Sieta T. de Vries Netherlands 13 207 1.0× 144 0.7× 121 0.6× 83 1.0× 16 0.3× 45 672
Kim A Bird United Kingdom 5 170 0.8× 294 1.4× 160 0.9× 59 0.7× 29 0.5× 5 423
Josep Maria Arnau Spain 10 132 0.6× 112 0.5× 170 0.9× 30 0.4× 38 0.7× 17 490
Consuelo Pedrós Spain 10 364 1.8× 189 0.9× 232 1.2× 95 1.2× 40 0.7× 18 558
Suzanne Braunschweig Switzerland 6 210 1.0× 156 0.8× 166 0.9× 198 2.4× 57 1.0× 8 492
Amanda Clarkson United Kingdom 5 215 1.0× 480 2.3× 173 0.9× 105 1.3× 61 1.1× 5 605
Katrin Farker Germany 10 97 0.5× 96 0.5× 134 0.7× 104 1.3× 20 0.4× 31 483
Lateef M. Khan Saudi Arabia 12 142 0.7× 91 0.4× 119 0.6× 43 0.5× 19 0.3× 27 431

Countries citing papers authored by Sabine Krebs

Since Specialization
Citations

This map shows the geographic impact of Sabine Krebs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sabine Krebs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sabine Krebs more than expected).

Fields of papers citing papers by Sabine Krebs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sabine Krebs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sabine Krebs. The network helps show where Sabine Krebs may publish in the future.

Co-authorship network of co-authors of Sabine Krebs

This figure shows the co-authorship network connecting the top 25 collaborators of Sabine Krebs. A scholar is included among the top collaborators of Sabine Krebs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sabine Krebs. Sabine Krebs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Fischer, Sarah, Marcel Vetter, Peter Dietrich, et al.. (2024). Reverse switching from the biosimilar SB2 to the originator infliximab in previously switched patients with inflammatory bowel diseases: results of a prospective long-term cohort study. Therapeutic Advances in Gastroenterology. 17. 1118484863–1118484863. 1 indexed citations
2.
3.
Krebs, Sabine, et al.. (2022). Ökonomische Aspekte bei der Versorgung von Patient*innen mit neuen oralen Tumortherapeutika: Erkenntnisse aus der AMBORA-Studie. Zeitschrift für Evidenz Fortbildung und Qualität im Gesundheitswesen. 169. 84–93. 7 indexed citations
4.
Fischer, Sarah, H Schmitt, Francesco Vitali, et al.. (2021). Long-term effectiveness, safety and immunogenicity of the biosimilar SB2 in inflammatory bowel disease patients after switching from originator infliximab. Therapeutic Advances in Gastroenterology. 14. 3974171666–3974171666. 19 indexed citations
5.
Fischer, Sarah, H Schmitt, Francesco Vitali, et al.. (2020). P548 Efficacy, safety, and pharmacokinetics after switching from infliximab originator to biosimilar SB2 in inflammatory bowel disease patients: A long-term observational, prospective cohort study. Journal of Crohn s and Colitis. 14(Supplement_1). S466–S467. 1 indexed citations
6.
Krebs, Sabine, et al.. (2020). Medication Safety in Intravenous Therapy: A Compatibility Study of Clonidine with Drugs Frequently Used in Intensive Care. Pharmaceutics. 13(1). 21–21. 8 indexed citations
7.
Krebs, Sabine, et al.. (2020). Assessing the quality of drug information provided by hospital pharmacies using a fictitious enquiry and simulated real-life conditions. European Journal of Hospital Pharmacy. 28(e1). e79–e84. 1 indexed citations
8.
9.
Steib–Bauert, Michaela, Winfried V. Kern, Holger Knoth, et al.. (2015). Hospital use of systemic antifungal drugs: a multi-center surveillance update from Germany. Infection. 43(4). 423–429. 26 indexed citations
10.
Krebs, Sabine, et al.. (2014). Evaluation of eight drug interaction databases commonly used in the German healthcare system. European Journal of Hospital Pharmacy. 22(3). 165–170. 9 indexed citations
11.
Dormann, Harald, Manfred Criegee‐Rieck, Antje Neubert, et al.. (2003). Lack of Awareness of Community-Acquired Adverse Drug Reactions Upon Hospital Admission. Drug Safety. 26(5). 353–362. 66 indexed citations
12.
Krebs, Sabine, et al.. (2002). Survey of Adverse Drug Reactions on a Pediatric Ward: A Strategy for Early and Detailed Detection. PEDIATRICS. 110(2). 254–257. 67 indexed citations
13.
Metz-Stavenhagen, P., Sabine Krebs, & Oliver Meier. (2001). Cervical fractures in conjunction with spondylitis ankylosans. Der Orthopäde. 30(12). 925–931. 24 indexed citations
14.
Krebs, Sabine, Harald Dormann, Uta Muth‐Selbach, et al.. (2001). Risperidone-induced cholestatic hepatitis. European Journal of Gastroenterology & Hepatology. 13(1). 67–69. 31 indexed citations
15.
Dormann, Harald, Sabine Krebs, Uta Muth‐Selbach, et al.. (2001). Adverse drug reactions in patients with gastroenterological diseases: does age increase the risk?. Alimentary Pharmacology & Therapeutics. 15(2). 171–180. 18 indexed citations
16.
Metz-Stavenhagen, P., Sabine Krebs, & H. Völpel. (2001). Surgical methods for handling complete kyphosis in cases of spondylitis ankylosans. Der Orthopäde. 30(12). 988–995. 3 indexed citations
17.
Dormann, Harald, Uta Muth‐Selbach, Sabine Krebs, et al.. (2000). Incidence and Costs of Adverse Drug Reactions During Hospitalisation. Drug Safety. 22(2). 161–169. 142 indexed citations
18.
Metz-Stavenhagen, P., et al.. (2000). Treatment of scoliosis and scoliokyphosis in patients with neurofibromatosis Recklinghausen (NF). Der Orthopäde. 29(6). 524–534. 7 indexed citations
19.
Krebs, Sabine, Harald Dormann, E. G. Hahn, H. T. Schneider, & Kay Brune. (2000). Unerwünschte Arzneimittelwirkungen. DMW - Deutsche Medizinische Wochenschrift. 125(33). 984–987.
20.
Tegeder, Irmgard, Jörn Lötsch, Sabine Krebs, et al.. (1999). Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clinical Pharmacology & Therapeutics. 65(5). 533–544. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Noblet Breakdown of academic impact, for papers by William N. Kelly Breakdown of academic impact, for papers by Sieta T. de Vries Breakdown of academic impact, for papers by Kim A Bird Breakdown of academic impact, for papers by Josep Maria Arnau Breakdown of academic impact, for papers by Consuelo Pedrós Breakdown of academic impact, for papers by Suzanne Braunschweig Breakdown of academic impact, for papers by Amanda Clarkson Breakdown of academic impact, for papers by Katrin Farker Breakdown of academic impact, for papers by Lateef M. Khan
Rankless by CCL
2026